Skip to main content
2022 Guide to Patient Support Services

MorphoSys

2022 Oncology Guide to Patient Support Services

MorphoSys Patient Support Services

855-421-6172

MorphoSys offers the My MISSION Support program to assist patients while taking Monjuvi (Table).

MY MISSION Support

This program has dedicated, specially trained professionals to support patient access to Monjuvi, including a Copay Assistance Program and the MorphoSys Foundation Patient Assistance Program.

Copay Assistance Program

Commercially insured patients taking Monjuvi may be able to receive assistance through the My MISSION Support Copay Assistance Program. Patients may be eligible if they:

  • Have private/commercial health insurance that covers the cost of Monjuvi
  • Do not participate in Medicare, Medicaid, Medicare Part D or Medicare Advantage plan, TRICARE, CHAMPUS, Puerto Rico Government Health Insurance Plan, or any other state or federal medical or pharmaceutical benefit program or pharmaceutical assistance program
  • Are a resident of the United States or Puerto Rico.

Click here to learn more or to enroll your patient in the Copay Assistance Program, or call 855-421-6172.

MorphoSys Foundation Patient Assistance Program

Patients may be able to obtain treatment with Monjuvi at no cost through the MorphoSys Foundation Patient Assistance Program. Eligibility is determined on a case-by-case basis. Patients may be eligible if they:

  • Meet the 2020 Federal Poverty Guidelines
  • Reside in the United States
  • Do not have insurance, or their copay responsibility through their insurer presents a financial hardship
  • Have a special circumstance related to COVID-19 that impacted their income or insurance coverage.

Click here to learn more or to enroll your patient in the MorphoSys Foundation Patient Assistance Program, or call 855-421-6172.

TABLE MorphoSys Oncology Drug

Drug
Indication
Patient support programs

Drug
Monjuvi (tafasitamab-cxix) injection
Indication
Treatment, in combination with lenalidomide, of adults with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, who are ineligible for autologous stem-cell transplant
Patient support programs

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"
Comments
(Optional)